271 related articles for article (PubMed ID: 19405787)
21. [CME: Legionella pneumonia].
Muggetti EMN; Fusi-Schmidhauser T; Schwarzenbach HR; Pons M
Praxis (Bern 1994); 2020; 109(8):658-664. PubMed ID: 32517597
[TBL] [Abstract][Full Text] [Related]
22. Persistently positive culture results in a patient with community-acquired pneumonia due to Legionella pneumophila.
Tan JS; File TM; DiPersio JR; DiPersio LP; Hamor R; Saravolatz LD; Stout JE
Clin Infect Dis; 2001 Jun; 32(11):1562-6. PubMed ID: 11340527
[TBL] [Abstract][Full Text] [Related]
23. In vitro and in vivo activities of sparfloxacin in Legionella infections.
Saito A; Gaja M
Drugs; 1995; 49 Suppl 2():250-2. PubMed ID: 8549320
[No Abstract] [Full Text] [Related]
24. Legionella pneumonia in hospitalized adults with respiratory failure: Quinolones or macrolides?
Ruiz-Spinelli A; Rello J
Eur J Intern Med; 2024 Feb; 120():62-68. PubMed ID: 37730517
[TBL] [Abstract][Full Text] [Related]
25. [Legionnaires' disease].
Toyoda K; Saito A
Nihon Rinsho; 1994 Feb; 52(2):384-8. PubMed ID: 8126890
[TBL] [Abstract][Full Text] [Related]
26. Azithromycin in the treatment of Legionella pneumonia requiring hospitalization.
Plouffe JF; Breiman RF; Fields BS; Herbert M; Inverso J; Knirsch C; Kolokathis A; Marrie TJ; Nicolle L; Schwartz DB
Clin Infect Dis; 2003 Dec; 37(11):1475-80. PubMed ID: 14614670
[TBL] [Abstract][Full Text] [Related]
27. Activities of tigecycline (GAR-936) against Legionella pneumophila in vitro and in guinea pigs with L. pneumophila pneumonia.
Edelstein PH; Weiss WJ; Edelstein MA
Antimicrob Agents Chemother; 2003 Feb; 47(2):533-40. PubMed ID: 12543655
[TBL] [Abstract][Full Text] [Related]
28. In vitro activity of gemifloxacin (SB-265805, LB20304a) against Legionella pneumophila and its pharmacokinetics in guinea pigs with L. pneumophila pneumonia.
Edelstein PH; Shinzato T; Doyle E; Edelstein MA
Antimicrob Agents Chemother; 2001 Aug; 45(8):2204-9. PubMed ID: 11451675
[TBL] [Abstract][Full Text] [Related]
29. Risk Factors, Management, and Outcomes of Legionella Pneumonia in a Large, Nationally Representative Sample.
Allgaier J; Lagu T; Haessler S; Imrey PB; Deshpande A; Guo N; Rothberg MB
Chest; 2021 May; 159(5):1782-1792. PubMed ID: 33352192
[TBL] [Abstract][Full Text] [Related]
30. Is a 5 day course of azithromycin enough for infections caused by Legionella pneumophila?
Matute AJ; Schurink CA; Hoepelman IM
J Antimicrob Chemother; 2000 Jun; 45(6):930-1. PubMed ID: 10837459
[No Abstract] [Full Text] [Related]
31. Is activity against "atypical" pathogens necessary in the treatment protocols for community-acquired pneumonia? Issues with combination therapy.
Bartlett JG
Clin Infect Dis; 2008 Dec; 47 Suppl 3():S232-6. PubMed ID: 18986295
[TBL] [Abstract][Full Text] [Related]
32. The treatment of Legionnaires' disease.
Dedicoat M; Venkatesan P
J Antimicrob Chemother; 1999 Jun; 43(6):747-52. PubMed ID: 10404312
[No Abstract] [Full Text] [Related]
33. In vitro and intracellular activities of peptide deformylase inhibitor GSK1322322 against Legionella pneumophila isolates.
Dubois J; Dubois M; Martel JF; Aubart K; Butler D
Antimicrob Agents Chemother; 2015 Jan; 59(1):707-10. PubMed ID: 25348534
[TBL] [Abstract][Full Text] [Related]
34. In vitro intracellular activity and in vivo efficacy of modithromycin, a novel bicyclolide, against Legionella pneumophila.
Sato T; Tateda K; Kimura S; Ishii Y; Yamaguchi K
Antimicrob Agents Chemother; 2011 Apr; 55(4):1594-7. PubMed ID: 21220530
[TBL] [Abstract][Full Text] [Related]
35. An outbreak of Legionnaires' disease associated with a circulating bathwater system at a public bathhouse. I: a clinical analysis.
Sasaki T; Matsumoto N; Nakao H; Katoh T; Fukuda Y; Nakazato M; Okayama A
J Infect Chemother; 2008 Apr; 14(2):117-22. PubMed ID: 18622674
[TBL] [Abstract][Full Text] [Related]
36. A Case of Community-Acquired Pneumonia Due to Legionella pneumophila Serogroup 9 Wherein Initial Treatment with Single-Dose Oral Azithromycin Appeared Useful.
Ito A; Ishida T; Tachibana H; Ito Y; Takaiwa T; Fujii H; Hashimoto T; Nakajima H; Amemura-Maekawa J
Jpn J Infect Dis; 2017 Nov; 70(6):660-662. PubMed ID: 28890505
[TBL] [Abstract][Full Text] [Related]
37. Legionnaires' disease: seek and ye shall find.
Yu VL
Cleve Clin J Med; 2001 Apr; 68(4):318-22. PubMed ID: 11326811
[TBL] [Abstract][Full Text] [Related]
38. Antibiotic Resistance and Azithromycin Resistance Mechanism of Legionella pneumophila Serogroup 1 in China.
Jia X; Ren H; Nie X; Li Y; Li J; Qin T
Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31405864
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of pazufloxacin mesilate in Legionnaires' disease: a case report and in vitro study of the isolate.
Higa F; Shinzato T; Toyama M; Haranaga S; Furugen M; Tateyama M; Kawakami K; Saito A
J Infect Chemother; 2005 Jun; 11(3):164-8. PubMed ID: 15990982
[TBL] [Abstract][Full Text] [Related]
40. In-vitro activity of levofloxacin against clinical isolates of Legionella spp, its pharmacokinetics in guinea pigs, and use in experimental Legionella pneumophila pneumonia.
Edelstein PH; Edelstein MA; Lehr KH; Ren J
J Antimicrob Chemother; 1996 Jan; 37(1):117-26. PubMed ID: 8647752
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
